Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, will present three scientific posters highlighting the progress of its investigational narcolepsy treatment Samelisant (SUVN-G3031) at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies (APSS) being held in Baltimore, United States.
The conference is regarded as one of the most important global gatherings for sleep medicine and sleep research professionals, bringing together clinicians, researchers, pharmaceutical companies, and healthcare experts focused on advancing treatments for sleep-related disorders.
Suven’s presentations will provide new insights into the development of Samelisant, including findings from its completed Phase 2 clinical study evaluating excessive daytime sleepiness (EDS) in narcolepsy patients, plans for a dedicated study targeting cataplexy in Type 1 narcolepsy, and the design of its global Phase 3 clinical programme known as the AWAKE study.
The company will present data demonstrating the therapeutic potential of Samelisant in addressing excessive daytime sleepiness, one of the most debilitating symptoms experienced by individuals living with narcolepsy. Researchers will also outline the scientific rationale behind a planned Phase 2 study focused on cataplexy, a condition characterized by sudden episodes of muscle weakness that significantly affect quality of life.
A third presentation will detail the design and development strategy for the upcoming Phase 3 clinical programme, which is expected to play a pivotal role in advancing Samelisant toward potential regulatory submissions and commercialization. In addition to the poster presentations, members of Suven’s scientific leadership team will engage with principal investigators, sleep medicine specialists, key opinion leaders, and potential strategic partners throughout the conference. These interactions are expected to support future clinical collaborations and strengthen the company’s global development efforts.
Suven Life Sciences has built a diversified pipeline targeting several neurological and psychiatric disorders with significant unmet medical needs. Alongside Samelisant, the company is advancing multiple clinical-stage candidates across indications including Alzheimer’s disease, major depressive disorder, cognitive impairment, Parkinson’s disease, schizophrenia, gastrointestinal disorders, and pain management.
The company currently maintains five clinical-stage assets and several research programmes at various stages of development. Through a combination of proprietary research, global intellectual property ownership, and focused clinical execution, Suven continues to strengthen its position in the CNS therapeutics landscape.
Beyond its clinical portfolio, Suven is advancing seven research-stage programs across multiple therapeutic indications, reflecting its commitment to innovation in neuroscience. The company retains global intellectual property rights for all its proprietary assets, providing a strong foundation for long-term value creation and future commercialization opportunities across major international markets.
